BMS wins FDA nod for new Orencia jab; Court reinstates Lilly's Strattera patent;

@FiercePharma: Pfizer nutritionals unit on deck for auction. Could be a $10.5B deal. Item | Follow @FiercePharma

> Bristol-Myers Squibb got the FDA nod for a subcutaneous form of Orencia, the rheumatoid arthritis drug previously available in an IV formulation. Story

> Eli Lilly won its appeal of a lower-court ruling that invalidated a 2017 patent on the popular ADHD drug Strattera, halting several generics versions in their tracks, at least for now. Report

> Vanda Pharmaceuticals inked a licensing deal with Argentina's Biotoscana Farma to launch its antipsychotic drug Fanapt in that country. Vanda release

> The global market for antipsychotic drugs reached $24.2 billion in 2010, more than one-third of the business for central nervous system meds. Release

> Pfizer's India unit posted a 19% increase in quarterly profits on net sales of 24.2 billion rupees, or $54.8 million; full Pfizer results are due Tuesday. Item

> Bosnia's biggest drug company, Bosnalijek, saw profits rise 1.5% on a 6.6% surge in revenues to 52 million marka, or about $38 million. Article

> Pharma distributor AmerisourceBergen is scouting for potential acquisitions in the distribution and packaging-services businesses. More

Biotech News

@FierceBiotech: BDO: Biotechs continue to rein in R&D costs, focus on top prospects. Piece | Follow @FierceBiotech

@JohnCFierce: Teva Ph3 for laquinimod (MS) fails. But they're planning apps in any case. (hmmmm) Report | Follow @JohnCFierce

@RyanMFierce: More Biogen coverage to come after trip to Boston, but first catching up on pipeline priorities: Story $BIIB | Follow @RyanMFierce

@MaureenFierce: Big Pharma's cutbacks are small biotechs' opportunity. Story via Seeking Alpha | Follow @MaureenFierce

> Biotechs show keen interest in new drugs for Down Syndrome. Article

> Teva's oral MS drug trips (again) in blockbuster Ph3 developmnt race. More

> Another setback for RNAi research as Merck shutters R&D outpost. News

> Ariad boosted by news of Merck's application for ridaforolimus. Item

> Immunotherapy developer Argos takes a run at $86M IPO. Report

> CRO Chiltern goes up on auction block. Story

Biotech IT News

> A free app to bypass Myriad's gene patent: How can gaming aid life science researchers? Item

> Survey: Developers stumble when projecting trial costs. Piece

> Sequencing giant BGI shoots for the cloud. More

> FDA eyes "value" of modeling used in drug development. News

> Ontario cancer group to get $40M deal, expand bioinformatics effort. Article

> PharmaPros teams up with Soltex, extends pharma reach. Story

> Eyeing big pharma needs, Icon xplains clinical tech buyout. Report

Medical Devices News

> CR Bard CFO to retire. Piece

> FDA Oks Medtronic study of second-generation pacing system. More

> World Heart to stop Levacore deelopment, reduce workforce. News

> Baxter establishs $200M venture arm. Report

> Boston Scientific to cut 1,400 jobs. Story

> Intuity closes $76M Series D financing. Article

> IOM report fuels debate over device reviews. More

And Finally... On second thought, human genes can be patented, a U.S. appeals court found. Report

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.